ClinicalTrials.gg
RecruitingNCT06828458DEFI-BURNUpdated Apr 23, 2026

Determining Elements of Anti-Fungal Immunity in BURN Patients

An observational study in Burn, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
327
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies in Burns with a site in France — 6 open to participants now, 7 under way, 2 of them phase 3. Burns · France.

Planned enrollment
3rd of 10
327 · median 72
Started
2025
with 2 others
Observational
10 of 32
2 open now
Registered
30th of 32
by date
Lead sponsor
5 of 32
Assistance Publique - Hôpitaux de Paris

Among the 32 studies in Burns with a site in France, this one is the 3rd largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2025, is one of 10 observational ones, and was the 30th registered.

Burns

906 studies on the registry are indexed under Burns; 165 are open to participants now.

Browse Burns studies →

Open to participants now

6 of the 32 studies in Burns with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 87 Burns studies recruiting now, 38 (44%) set no upper age limit and 38 (44%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Burns with a site in France, or all of them as a file.
02

Study summary

Scientific justification Invasive fungal diseases (IFDs) pose a substantial threat, especially in immunocompromised patients, necessitating urgent research focus and therapeutic advancements. The IFI-BURN study, involving a cohort of patients with severe burn injury (n=276), revealed a significant IFD incidence of 31.6% and underscored their critical impact on morbidity and mortality. While fungi are present everywhere, for moulds within the environment and for yeasts within our microbiota, why certain patients develop IFDs and others do not, remains poorly understood. The answer most likely resides in the impact of the burn injury on the immune response, loss of skin barrier and particular predisposing immune phenotype of patients. The immune system is composed of both cellular and humoral components, but the latter is far less studied in antifungal immunity although they exert multiple antimicrobial mechanisms.

03

Conditions studied

  • Burn

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with burn injury

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Burn patients

  • Adult patients ≥ 18 years old
  • Admission \< 4 days following burn injury
  • Total burn surface Area ≥ 15%
  • Non opposition of the patient or his/her relatives to the research
  • Affiliation to social security or any health insurance

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Opposition of the patient or his/her relatives
  • Decision not to resuscitate or to limit or stop active therapies
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
327 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Adult patients with burn injury

    Other: Biological sampling

Interventions

  • OtherBiological sampling

    Whole blood on EDTA sample 2 tubes (5mL) PAXgene sample 1 tube (2.5 mL) Rectal swab Skin swab (1 swab for 5 anatomically burned sites) At day 0, day 3, day 7, day 14, day 21

06

What researchers measure

Primary outcomes

  1. Invasive fungal disease (IFD) onset during hospitalisation time

    Proven IFD according to EORTC/MSGERC criteria applicable for invasive candidiasis. Putative invasive mold infection is defined with ≥ 2 positive culture from skin biopsy/bronchoalveolar lavage or ≥ 2 positive blood specific qPCR (aspergilosis, mucorales, fusariosis) or a combination of both. Possible invasive mold infection is defined with only one positive mycological criterion.

    Time frame: Up to 18 months

Secondary outcomes

  1. Overall survival

    Time frame: At day 30

  2. Overall survival

    Time frame: At day 90

  3. Hospital mortality

    Time frame: Up to 18 months

  4. Incidence of organ failure during hospitalisation

    * Acute respiratory distress syndrome defined by the modified Berlin criteria, or * Acute kidney injury as defined by the KDIGO consensus, or * Septic shock and doses of catecholamines defined by SEPSIS-3

    Time frame: Up to 18 months

  5. Severity score at admission

    SAPS 2 : Simplified Acute Physiology Score II The score can range from 0 to 163. Higher score indicates more severe illness and a higher risk of mortality. Lower score indicates less severe illness and a lower risk of mortality.

    Time frame: At inclusion

  6. Severity score at admission

    ABSI Acute Bowel Ischemia Severity Index The score ranges from 0 to 10. A higher score indicates a more severe case and a higher risk of mortality.

    Time frame: At inclusion

  7. Severity score at admission

    SOFA score : Sequential Organ Failure Assessment The score can range from 0 to 24, with higher scores indicating more severe organ failure and a worse prognosis.

    Time frame: At inclusion

  8. Number of days without renal replacement therapy

    Time frame: At day 30

  9. Number of days without mechanical ventilation

    Time frame: At day 30

  10. Length of stay in Intensive Care Unit

    Time frame: Up to 18 months

  11. Length of stay in hospital

    Time frame: Up to 18 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Oct 2030, 66 months after the start.

Of 58 non-industry observational studies under Burns, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 56. This study's planned 66 months is above that.

Counting every sponsor, half of 70 studies reached it within 24 months; a quarter within 14 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2025
First posted
Feb 14, 2025
StartActual
Apr 23, 2025
Primary completionEst.
Oct 23, 2030
CompletionEst.
Oct 23, 2030
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06828458
Responsible party
Sponsor
First posted
Feb 14, 2025
Start date
Apr 23, 2025
Primary completion
Oct 23, 2030 (estimated)
Completion
Oct 23, 2030 (estimated)
Last update
Apr 23, 2026

Study contacts

Emmanuel Dudoignon, MD
Contact
emmanuel.dudoignon@aphp.fr
1 42 49 93 94 ext. +33
Jérôme Lambert, MD PhD
Contact
jerome.lambert@u-paris.fr
+33142499742 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion